ACADIA Pharmaceuticals Inc.
ACAD
Κατάταξη σε μετοχές
#4483
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Τιμή μετοχής
$20.20
Κεφαλαιοποίηση
$3.48B
Αλλαγή (1 ημέρα)
2.02%
Αλλαγή (1 έτος)
-3.53%
Χώρα
US
Εμπόριο ACADIA Pharmaceuticals Inc. (ACAD)
Κατηγορία
Healthcare
Δείκτης P/S για ACADIA Pharmaceuticals Inc. (ACAD)
Δείκτης P/S στις October 2026 TTM: 2.89
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της ACADIA Pharmaceuticals Inc., ο τρέχων δείκτης P/S (TTM) είναι 2.89. Στο τέλος του 2023, ο δείκτης ήταν 7.06.
Ιστορικό P/S για την ACADIA Pharmaceuticals Inc. από 2000 έως 2026
Δείκτης P/S στο τέλος κάθε έτους
| Έτος | P/S Ratio | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 2.89 | -8.68% |
| 2024 | 3.17 | -55.03% |
| 2023 | 7.06 | 41.88% |
| 2022 | 4.98 | -35.68% |
| 2021 | 7.74 | -59.36% |
| 2020 | 19.04 | 2.52% |
| 2019 | 18.57 | 103.07% |
| 2018 | 9.15 | -69.06% |
| 2017 | 29.56 | -84.67% |
| 2016 | 192.80 | -99.67% |
| 2015 | 58.81K | 128.57% |
| 2014 | 25.73K | 1,275.39% |
| 2013 | 1.87K | 3,498.15% |
| 2012 | 51.99 | 90.69% |
| 2011 | 27.27 | 2,380.70% |
| 2010 | 1.10 | -85.78% |
| 2009 | 7.73 | -63.20% |
| 2008 | 21.01 | -59.28% |
| 2007 | 51.59 | 70.96% |
| 2006 | 30.18 | 52.49% |
| 2005 | 19.79 | 30.01% |
| 2004 | 15.22 | 1,049.01% |
| 2003 | 1.32 | -14.53% |
| 2002 | 1.55 | -28.86% |
| 2001 | 2.18 | 31.07% |
| 2000 | 1.66 | 0.00% |
Δείκτης P/S για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | P/S Ratio | Διαφορά P/S Ratio | Χώρα |
|---|---|---|---|
| 10.02 | 246.20% |
US
|
|
| 40.55 | 1,300.77% |
US
|
|
| 3.96 | 36.83% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 250.49% |
NL
|
